Filing Flows › CytomX Therapeutics (CTMX) › Q1 2026
CytomX Therapeutics (CTMX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
CytomX Therapeutics (CTMX) reported revenue of $10.3M for the first quarter 2026 (Q1 2026), -80% from a year earlier and up 15-fold from the quarter before. Operating margin was -191.8%, net loss $18.2M (177.9% of revenue).
CytomX Therapeutics, Q1 2026: revenue $10.3M (-80% year over year), operating margin -191.8%, net loss $18.2M, operating cash flow −$25.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.3M | 15× | -80% |
| Operating profit | −$19.7M | — | -187% |
| Net earnings | −$18.2M | — | -178% |
| Operating cash flow | −$25.5M | — | — |
What changed
Revenue was $10.3M in Q1 2026, down 80% year over year and up 1447% from the previous quarter.
Operating costs exceeded revenue by $19.7M, an operating margin of -191.8%. Total costs grew 6% against a revenue fall of 80%. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $18.2M, narrower than the previous quarter's $26.5M loss.
Operating cash flow was −$25.5M. Non-cash charges added back $4.7M of share-based compensation. Working capital and other items used $12.0M.
Questions
What was CytomX Therapeutics' revenue in the first quarter 2026?
CytomX Therapeutics (CTMX) reported revenue of $10.3M for the first quarter 2026 (Q1 2026), -80% from a year earlier and up 15-fold from the quarter before.
Was CytomX Therapeutics profitable in the first quarter 2026?
Operating loss was $19.7M (-191.8% of revenue) and net loss $18.2M.